Skip to main content
. 2006 Nov 7;95(11):1504–1513. doi: 10.1038/sj.bjc.6603459

Figure 6.

Figure 6

Growth characteristics and EGFR signalling of gefitinib-resistant GLM-1 cells (GLM-1R). (A) Comparison of growth inhibition by gefitinib in vitro between GLM-1 (•) and GLM-1R (▴) cells. *P<0.01. (B) Effect of gefitinib on the growth of subcutaneous GLM-1R tumour xenograft in nude mice. Gefitinib was orally administered at a dose of 0 (•) and 100 mg per kg per day (▴), five times per week for 3 weeks. NS, not significant (P=0.69 vs control). (C) Comparison of histology and EGFR expression between GLM-1 and GLM-1R tumour xenograft in nude mice by immunohistochemistry. Cell surface EGFR expression was increased in GLM-1R cells. (D) Comparison of phosphorylation of Shc, Akt and Erk1/2 between GLM-1 and GLM-1R cells. Phosphorylation of Shc and Erk1/2 was increased in GLM-1R cells. Bars=s.e.